Medincell SA Asset Resilience Ratio

Latest as of March 2026: 20.39%

Medincell SA asset resilience ratio. Medincell SA (MEDCL) has an Asset Resilience Ratio of 20.39% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medincell SA liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€22.03 Million
≈ $25.76 Million USD Cash + Short-term Investments

Total Assets

€108.05 Million
≈ $126.33 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Medincell SA (2016–2026)

Asset resilience ratio of Medincell SA from 2016 to 2026. This chart shows how Medincell SA's Asset Resilience Ratio has changed over time. Read Medincell SA debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Medincell SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Medincell SA.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €22.03 Million 20.39%
Total Liquid Assets €22.03 Million 20.39%

Asset Resilience Insights

  • Good Liquidity Position: Medincell SA maintains a healthy 20.39% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Medincell SA Industry Peers by Asset Resilience Ratio

Compare Medincell SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Medincell SA Asset Resilience Ratio by Year (2016–2026)

Medincell SA asset resilience ratio by year from 2016 to 2026. The table below shows the annual Asset Resilience Ratio data for Medincell SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2026-03-31 20.39% €22.03 Million
≈ $25.76 Million
€108.05 Million
≈ $126.33 Million
-39.09pp
2025-03-31 59.48% €53.80 Million
≈ $62.90 Million
€90.45 Million
≈ $105.75 Million
+31.55pp
2024-03-31 27.93% €10.32 Million
≈ $12.06 Million
€36.95 Million
≈ $43.20 Million
+27.92pp
2023-03-31 0.01% €3.00K
≈ $3.51K
€29.34 Million
≈ $34.30 Million
-15.72pp
2022-03-31 15.73% €6.97 Million
≈ $8.15 Million
€44.30 Million
≈ $51.79 Million
+6.65pp
2021-03-31 9.08% €5.78 Million
≈ $6.75 Million
€63.61 Million
≈ $74.36 Million
-6.81pp
2020-03-31 15.89% €4.34 Million
≈ $5.07 Million
€27.31 Million
≈ $31.92 Million
-24.90pp
2019-03-31 40.80% €15.49 Million
≈ $18.12 Million
€37.98 Million
≈ $44.40 Million
+40.66pp
2018-03-31 0.14% €35.00K
≈ $40.92K
€25.35 Million
≈ $29.64 Million
-19.26pp
2017-03-31 19.40% €4.51 Million
≈ $5.28 Million
€23.27 Million
≈ $27.20 Million
+2.62pp
2016-03-31 16.78% €1.88 Million
≈ $2.19 Million
€11.17 Million
≈ $13.06 Million
--
pp = percentage points

About Medincell SA

PA:MEDCL France Biotechnology
Market Cap
$1.11 Billion
€946.58 Million EUR
Market Cap Rank
#9567 Global
#152 in France
Share Price
€26.36
Change (1 day)
+0.38%
52-Week Range
€20.24 - €37.62
All Time High
€38.46
About

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment … Read more